<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033278</url>
  </required_header>
  <id_info>
    <org_study_id>CMMo/MD/2013</org_study_id>
    <nct_id>NCT02033278</nct_id>
  </id_info>
  <brief_title>Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.</brief_title>
  <official_title>Multicenter Phase IIb Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iniciativa Andaluza en Terapias Avanzadas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Network for Design and Translation of Advanced Therapies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial phase IIb, double-blind, randomized, controlled with placebo. There is&#xD;
      sufficient preliminary evidence to consider intracoronary injection of bone marrow progenitor&#xD;
      cells as a viable, safe and beneficial treatment in patients with dilated cardiomyopathy,&#xD;
      although the biological mechanism of action of bone marrow cells in the myocardium is not&#xD;
      known. In this project we propose to investigate comparatively and from a biological and&#xD;
      clinical point of view the applicability of regenerative therapy with autologous bone marrow&#xD;
      cells in patients with dilated cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population correspond to male and female patients with idiopathic dilated&#xD;
      cardiomyopathy.&#xD;
&#xD;
      51 patients diagnosed with this disease are included. After inclusion, will proceed to the&#xD;
      random allocation to study group or control group in a 2:1 ratio, 34 patients in the&#xD;
      treatment group and 17 in the control group.&#xD;
&#xD;
      The total duration is expected to be 48 months: The inclusion period is 24 months and each&#xD;
      patient assigned to the experimental group will be followed for 24 months, whereas that one&#xD;
      ramdomized to the control group, will have a folow-up of 12 months. Upon completion there of,&#xD;
      the patients will be followed in routine clinical practice.&#xD;
&#xD;
      This is a double blind study, in which all patients will perform the bone marrow harvesting.&#xD;
&#xD;
      All patients will receive the best medical treatment individualized (ACEIs or Angiotensin II&#xD;
      receptor blocker, beta-blockers, diuretics and eplerenone) for at least 6 months prior to&#xD;
      their participation in the clinical trial, so that the situation is stable and&#xD;
      pharmacological basal condition is the same for everyone.&#xD;
&#xD;
      The bone marrow cells of patients assigned to placebo group will be cryopreserved, and once&#xD;
      the trial is completed, the blind will be opened and all the patients who had been randomized&#xD;
      to the control group, may be processed by the route of compassionate use with their own&#xD;
      mononuclear bone marrow cells previously frozen.&#xD;
&#xD;
      The patients who are randomized to experimental group will be treated by the conventional&#xD;
      treatment + infusion of autologous mononuclear bone marrow cells not expanded whereas the&#xD;
      patients who are randomized to control group will be treated by the conventional treatment +&#xD;
      infusion of placebo.&#xD;
&#xD;
      The main objective is to assess comparative the efficacy of intracoronary injection of bone&#xD;
      marrow stem cells autologous to improve ventricular function in patients with idiopathic&#xD;
      dilated cardiomyopathy who receive conventional medical treatment, compared with a control&#xD;
      group who receive a infusion of placebo and conventional medical treatment. The improvement&#xD;
      in ventricular function assessed by changes in angiographically determined ejection fraction.&#xD;
&#xD;
      Secondary objectives of the study are:&#xD;
&#xD;
      - To analyze the predictors of good clinical response, functional and biological treatment&#xD;
      with adult stem cells autologous mononuclear bone marrow not expanded in terms of functional&#xD;
      recovery.&#xD;
&#xD;
      The following parameters were evaluated: Functional class (NYHA), Natriuretic peptide B,&#xD;
      Stress test (exercise time), Echocardiographic parameters of ventricular function, for&#xD;
      example LVEF (%), TDV (ml), TSV (ml) and TAPSE (ms) and Biological parameters of cellular&#xD;
      functionality, for example CD133 +, CD34 +, CD34 +/CD177 + and CD34 +/CD38- (in %).&#xD;
&#xD;
      - To determine, in the light of the obtained results, the application protocol suitable cell&#xD;
      therapy for the treatment of dilated cardiomyopathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment rate, bibliographic evidence of lack of efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">January 6, 2014</start_date>
  <completion_date type="Actual">April 21, 2020</completion_date>
  <primary_completion_date type="Actual">October 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in ventricular function measured angiographically.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of clinical improvement based on the absence of major cardiac events (MACE) during follow-up.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and analytical progress (NYHA grade &amp; BNP)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of evolution since diagnosis of idiopathic dilated cardiomyopathy prior to study entry.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional recovery as measured with ergometry</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography and Electrocardiography variables</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Idiopathic Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Infusion of autologous mononuclear bone marrow cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusion plus conventional medical treatment (as indicated by clinician)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infusion of autologous mononuclear bone marrow cells</intervention_name>
    <description>Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)</description>
    <arm_group_label>Infusion of autologous mononuclear bone marrow cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Placebo infusion plus conventional medical treatment (as indicated by clinician)</description>
    <arm_group_label>Placebo infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both sexes and ages between 18 and 70 years.&#xD;
&#xD;
          2. Patients diagnosed with dilated cardiomyopathy established by echocardiography.&#xD;
&#xD;
          3. Minimum evolution since diagnosis of 6 months.&#xD;
&#xD;
          4. Absence of coronary injury tested with multislice CT and/or hemodynamic study&#xD;
             performed after study entry, or within the previous 36 months (or before in specific&#xD;
             low risk clinical profiles) if no angina symptomatology is present.&#xD;
&#xD;
          5. Patients receiving optimized medical therapy for at least 6 months prior to enrollment&#xD;
             (individually adjusted according to functional status).&#xD;
&#xD;
          6. Ejection fraction of the left ventricle &lt;40% or ejection fraction of the left&#xD;
             ventricle 40% -50% if left ventricular tele-diastolic volume is &gt; 110 ml/m2.&#xD;
&#xD;
          7. Presence of sinus rhythm.&#xD;
&#xD;
          8. Writen informed consent for participation in the trial.&#xD;
&#xD;
          9. Normal laboratory parameters, defined by: Leukocytes ≥ 3000; Neutrophils ≥ 1500;&#xD;
             Platelets ≥ 100,000; Aspartate aminotransferase / Alanine aminotransferase ≤ 2.5&#xD;
             standard range institution; Creatinine ≤ 2.5 mg / dL; Haemoglobin &gt; 9 g/dL&#xD;
&#xD;
         10. Women of childbearing potential must have negative results on a pregnancy test and&#xD;
             agree to use medically approved methods of contraception thoughout follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary Dilated cardiomyopathy.&#xD;
&#xD;
          2. Recent history of myocarditis (&lt; 6 months prior to study entry).&#xD;
&#xD;
          3. Patients amenable to receive cardiac resynchronization therapy&#xD;
&#xD;
          4. Patients in active waiting list for heart transplantation.&#xD;
&#xD;
          5. Coexistence of other serious systemic diseases.&#xD;
&#xD;
          6. Coexistence of any type of blood disease&#xD;
&#xD;
          7. Pregnant or breastfeeding women; or women of childbearing potential not comminting to&#xD;
             use effective contraception.&#xD;
&#xD;
          8. Patients who are currently participating, or have completed their participation in a&#xD;
             clinical trial within the last 3 months. Patients who have participated in any&#xD;
             advanced therapies clinical trial any time previously.&#xD;
&#xD;
          9. Patients with malignant or pre-malignant tumors.&#xD;
&#xD;
         10. Positive serology for hepatitis B virus, hepatitis C virus or human immunodeficiency&#xD;
             virus.&#xD;
&#xD;
         11. Use of any protocolo prohibited medication. A wash-out period of 2 months can be&#xD;
             considered for inclusion in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Romero Moreno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Sobrino Marquez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis A Iñigo García, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Costa del Sol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Zayas Rueda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel De Mora Martín, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Regional U. Carlos Haya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia López Fernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen de las Nieves</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Francisco Díaz Fernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Juan Ramón Jimenez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Oneto Otero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Jerez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Ruiz Salmerón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopistal Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Juan Ramón Jimenez</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional U. Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.juntadeandalucia.es/terapiasavanzadas/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

